Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.79
ACUR's Cash to Debt is ranked higher than
53% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.47 vs. ACUR: 1.79 )
Ranked among companies with meaningful Cash to Debt only.
ACUR' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 0.22 Max: No Debt
Current: 1.79
Equity to Asset 0.46
ACUR's Equity to Asset is ranked lower than
73% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. ACUR: 0.46 )
Ranked among companies with meaningful Equity to Asset only.
ACUR' s Equity to Asset Range Over the Past 10 Years
Min: -7.86  Med: -0.63 Max: 0.97
Current: 0.46
-7.86
0.97
F-Score: 5
Z-Score: -25.66
M-Score: 17.25
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -89.27
ACUR's Operating margin (%) is ranked lower than
89% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.51 vs. ACUR: -89.27 )
Ranked among companies with meaningful Operating margin (%) only.
ACUR' s Operating margin (%) Range Over the Past 10 Years
Min: -11455.28  Med: -352.02 Max: 51.47
Current: -89.27
-11455.28
51.47
Net-margin (%) -105.16
ACUR's Net-margin (%) is ranked lower than
90% of the 684 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.44 vs. ACUR: -105.16 )
Ranked among companies with meaningful Net-margin (%) only.
ACUR' s Net-margin (%) Range Over the Past 10 Years
Min: -11301.63  Med: -383.78 Max: 50.74
Current: -105.16
-11301.63
50.74
ROE (%) -105.56
ACUR's ROE (%) is ranked lower than
95% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.23 vs. ACUR: -105.56 )
Ranked among companies with meaningful ROE (%) only.
ACUR' s ROE (%) Range Over the Past 10 Years
Min: -114.99  Med: -46.85 Max: 51.89
Current: -105.56
-114.99
51.89
ROA (%) -38.79
ACUR's ROA (%) is ranked lower than
88% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. ACUR: -38.79 )
Ranked among companies with meaningful ROA (%) only.
ACUR' s ROA (%) Range Over the Past 10 Years
Min: -357.3  Med: -43.29 Max: 33.14
Current: -38.79
-357.3
33.14
ROC (Joel Greenblatt) (%) -551.68
ACUR's ROC (Joel Greenblatt) (%) is ranked lower than
89% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.81 vs. ACUR: -551.68 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ACUR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1226.13  Med: -945.65 Max: 1628.06
Current: -551.68
-1226.13
1628.06
Revenue Growth (3Y)(%) -66.50
ACUR's Revenue Growth (3Y)(%) is ranked lower than
98% of the 581 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. ACUR: -66.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ACUR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -54.30 Max: 27.3
Current: -66.5
0
27.3
» ACUR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

ACUR Guru Trades in Q4 2014

Jim Simons 91,500 sh (+103.79%)
» More
Q1 2015

ACUR Guru Trades in Q1 2015

Jim Simons 128,900 sh (+40.87%)
» More
Q2 2015

ACUR Guru Trades in Q2 2015

Jim Simons 177,700 sh (+37.86%)
» More
Q3 2015

ACUR Guru Trades in Q3 2015

Jim Simons 48,820 sh (-72.53%)
» More
» Details

Insider Trades

Latest Guru Trades with ACUR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.78
ACUR's P/B is ranked higher than
51% of the 928 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.54 vs. ACUR: 2.78 )
Ranked among companies with meaningful P/B only.
ACUR' s P/B Range Over the Past 10 Years
Min: 1.6  Med: 4.83 Max: 15.93
Current: 2.78
1.6
15.93
P/S 3.27
ACUR's P/S is ranked lower than
61% of the 929 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.60 vs. ACUR: 3.27 )
Ranked among companies with meaningful P/S only.
ACUR' s P/S Range Over the Past 10 Years
Min: 2.8  Med: 34.52 Max: 990
Current: 3.27
2.8
990
Current Ratio 4.18
ACUR's Current Ratio is ranked higher than
75% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. ACUR: 4.18 )
Ranked among companies with meaningful Current Ratio only.
ACUR' s Current Ratio Range Over the Past 10 Years
Min: 0.02  Med: 1.16 Max: 68.17
Current: 4.18
0.02
68.17
Quick Ratio 4.16
ACUR's Quick Ratio is ranked higher than
79% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. ACUR: 4.16 )
Ranked among companies with meaningful Quick Ratio only.
ACUR' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 0.89 Max: 68.17
Current: 4.16
0.01
68.17
Days Inventory 157.57
ACUR's Days Inventory is ranked lower than
69% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 119.42 vs. ACUR: 157.57 )
Ranked among companies with meaningful Days Inventory only.
ACUR' s Days Inventory Range Over the Past 10 Years
Min: 446.2  Med: 599.31 Max: 752.41
Current: 157.57
446.2
752.41
Days Sales Outstanding 9.47
ACUR's Days Sales Outstanding is ranked higher than
94% of the 584 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.67 vs. ACUR: 9.47 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACUR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.73  Med: 33.98 Max: 575.69
Current: 9.47
2.73
575.69
Days Payable 169.88
ACUR's Days Payable is ranked higher than
85% of the 563 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.59 vs. ACUR: 169.88 )
Ranked among companies with meaningful Days Payable only.
ACUR' s Days Payable Range Over the Past 10 Years
Min: 348.92  Med: 613.10 Max: 877.28
Current: 169.88
348.92
877.28

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.77
ACUR's Price/Net Cash is ranked higher than
69% of the 284 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.02 vs. ACUR: 4.77 )
Ranked among companies with meaningful Price/Net Cash only.
ACUR' s Price/Net Cash Range Over the Past 10 Years
Min: 2.79  Med: 6.84 Max: 494
Current: 4.77
2.79
494
Price/Net Current Asset Value 4.18
ACUR's Price/Net Current Asset Value is ranked higher than
71% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. ACUR: 4.18 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ACUR' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.74  Med: 6.75 Max: 90.32
Current: 4.18
2.74
90.32
Price/Tangible Book 3.42
ACUR's Price/Tangible Book is ranked higher than
55% of the 889 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.76 vs. ACUR: 3.42 )
Ranked among companies with meaningful Price/Tangible Book only.
ACUR' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.64  Med: 6.41 Max: 79.25
Current: 3.42
2.64
79.25
Price/Median PS Value 0.09
ACUR's Price/Median PS Value is ranked higher than
99% of the 899 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.15 vs. ACUR: 0.09 )
Ranked among companies with meaningful Price/Median PS Value only.
ACUR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.01  Med: 0.14 Max: 27.14
Current: 0.09
0.01
27.14
Earnings Yield (Greenblatt) (%) -32.03
ACUR's Earnings Yield (Greenblatt) (%) is ranked lower than
93% of the 720 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. ACUR: -32.03 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ACUR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -37.27  Med: 8.70 Max: 48.2
Current: -32.03
-37.27
48.2

More Statistics

Revenue(Mil) $6
EPS $ -0.61
Beta2.17
Short Percentage of Float0.49%
52-Week Range $1.61 - 6.75
Shares Outstanding(Mil)11.80

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 8 5 14
EPS($) -0.17 -0.21 -0.05
EPS without NRI($) -0.17 -0.21 -0.05

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:HD4B.Germany,
Acura Pharmaceuticals Inc is a specialty pharmaceutical company engaged in the research, development and commercialization of products intended to address medication abuse and misuse, utilizing its proprietary Aversion and Impede Technologies. The Company has discovered and developed two proprietary technologies; Aversion Technology and Impede Technology. Its Aversion Technology is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules intended to address some common methods of product tampering associated with opioid abuse. Pfizer Inc.s Oxecta or oxycodone HCl tablets CII is the first approved and marketed product utilizing Aversion and is commercialized under its license agreement with a subsidiary of Pfizer, or the Pfizer Agreement. The Company has also developed its Impede Technology which is a combination of inactive ingredients that prevent the extraction of pseudoephedrine from tablets and disrupt the direct conversion of pseudoephedrine from tablets into methamphetamine. It has 7 additional opioid products utilizing Aversion in various stages of development. It also launched Nexafed commercially in mid-December 2012. The Pfizer Agreement grants Pfizer an exclusive license to develop and commercialize Oxecta. Its potential competitors include, Pain Therapeutics, in collaboration with Pfizer, Purdue Pharma, Atlantic Pharmaceuticals, Egalet Corporation, KemPharm, Shionogi, Nektar Therapeutics, Signature Therapeutics, QRx Pharma, Tris Pharma, Pisgah Labs, and Collegium Pharmaceuticals, Inc. The Company is subject to extensive regulation by the federal government, principally by the FDA under the Federal Food, Drug and Cosmetic Act, or the FD&C Act and to a lesser extent, by state and local governments.
» More Articles for ACUR

Headlines

Articles On GuruFocus.com
What to Watch for: November 3-7 Nov 04 2014 
Acura Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 01 2011 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 02 2010 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) Jul 29 2010 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) Oct 26 2009 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) Jul 30 2009 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) May 01 2009 

More From Other Websites
Acura Pharmaceuticals Provides Development Update on Its LIMITX(TM) Abuse Deterrent Technology Feb 01 2016
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Other Events Feb 01 2016
Acura Pharmaceuticals Provides Development Update on Its LIMITX(TM) Abuse Deterrent Technology Feb 01 2016
Acura Pharmaceuticals Provides Development Update on Its LIMITX(TM) Abuse Deterrent Technology Dec 17 2015
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Other Events Dec 17 2015
Acura Pharmaceuticals Provides Development Update on Its LIMITX(TM) Abuse Deterrent Technology Dec 17 2015
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Change in Directors or Principal Officers Dec 16 2015
ACURA PHARMACEUTICALS, INC Financials Dec 08 2015
How Does Smart Money Feel About Acura Pharmaceuticals, Inc. (ACUR)? Nov 24 2015
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Other Events Nov 10 2015
Acura Pharmaceuticals Receives 2015 Frost & Sullivan North American Opioid Oral Abuse Deterrence... Nov 10 2015
Acura Pharmaceuticals Receives 2015 Frost & Sullivan North American Opioid Oral Abuse Deterrence... Nov 10 2015
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 05 2015
ACURA PHARMACEUTICALS, INC Files SEC form 10-Q, Quarterly Report Nov 04 2015
Acura Pharmaceuticals Announces Third Quarter 2015 Financial Results Nov 04 2015
Acura Pharmaceuticals Announces Third Quarter 2015 Financial Results Nov 04 2015
Acura Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ACUR) : October 30, 2015 Oct 30 2015
Acura Pharmaceuticals to Host Third Quarter 2015 Financial Results Conference Call on November 5,... Oct 28 2015
Acura Pharmaceuticals to Host Third Quarter 2015 Financial Results Conference Call on November 5,... Oct 28 2015
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Other Events Oct 13 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK